Schedule 13G ownership disclosure
X4 Pharmaceuticals Inc
Common Stock, par value $0.001 per share · CUSIP: 98420X202
Event date: 2025-10-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLC
Shares: 6,064,680 · Class: 7.6%
- Joseph Edelman
Shares: 6,064,680 · Class: 7.6%
- Perceptive Life Sciences Master Fund, Ltd.
Shares: 6,064,680 · Class: 7.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-262560
- Form type
- SCHEDULE 13G
- Filer
- PERCEPTIVE ADVISORS LLC
- CIK
- CIK 1224962
- Filed
- Nov 03, 2025
- Reporting period
- Oct 27, 2025
- Description
- Schedule 13G beneficial ownership